Long term outcome of patients with acquired haemophilia - A monocentre interim analysis of 82 patients

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 223-228

  Zeitler, H ^a   Goldmann, G ^a   Marquardt, N ^a   Ulrich Merzenich, G ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Acquired haemophilia; APTT; FVIII; Immune tolerance induction MBMP protocol; Immunmodulation; Immunoadsorption

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PROTHROMBIN; RITUXIMAB; VINCRISTINE;

ACQUIRED HAEMOPHILIA; ACQUIRED HEMOPHILIA; ADULT; AGED; ANTIBODY TITER; APHERESIS; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL DECISION MAKING; COMORBIDITY; DISEASE PREDISPOSITION; EXTRACORPOREAL CIRCULATION; FATALITY; FEMALE; HEMOPHILIA; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PARTIAL THROMBOPLASTIN TIME; PLASMA VOLUME; PRIORITY JOURNAL; REMISSION; SURGERY; TREATMENT DURATION; TREATMENT RESPONSE;

ADSORPTION; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; FACTOR VIII; FEMALE; GERMANY; HEMATINICS; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872866374     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.033     Document Type: Article

References (13)

1. Collin P.W., Hirsch S., Baglin T.P. Acquired hemophilia in the United Kingdom: a 2 year national surveillance study by the United Kingdom Haemophilia Centre Doctors Organisation. Blood 2007, 109:1870-1877.
2. Collin P., Baudo F., Knoebel P., et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012, prepublished online April 18, 2012. 10.1182/blood-2012-02-409185.
3. Collin P., Baudo F., Knoebel P., et al. Management of bleeding in acquired haemophilia A(AHA): results from the European Acquired Haemophilia Registry (EACH2). Blood 2012, prepublished online May 22, 2012. 10.1182/blood-2012-02-408930.
4. Sumner M.J., Geldziler B.D., Pedersen M., Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007, 13(5):451-461.
5. Aouba A., Rey G., Pavillon G., et al. Deaths associated with acquired haemophilia in France from 2000 to 2009: multiple cause analysis for best care strategies. Haemophilia 2011, 13:1365-2516.
6. Giles A.R., Verbruggen B., Roivard G.E., Walker I., the Association of Haemophilia Centre of Canada A detailed comparison of the performance of the standard versus Nijmegen modification of the Bethesda assay in detecting factor VIII: inhibitors in the haemophilia a population of Canada. Haemostasis 1998, 79:872-875.
7. Zeitler H., Ulrich-Merzenich G., Hess L. Treatment of acquired hemophilia by the Bonn-Malmö protocol: documentation of an in vivo immunomodulating concept. Blood 2005, 105:2287-2293.
8. Zeitler H., Ulrich-Merzenich G., Walger P. Treatment of factor VIII inhibitors with selective IgG immunoadsorption - a single centre experience in 50 patients with acquired hemophilia. Transfus Med Hemother 2006, 33:160-164.
9. Zeitler H., Ulrich-Merzenich G., Walger P., Düsing R., Vetter H., Brackmann H.H. Das modifizierte Bonn-Malmö Protokoll in der Behandlung der erworbenen Hemmkörperhämophilie -eine multimodale Therapiestrategie. Dtsch Med Wochenschr 2006, 131:141-147.
10. Zeitler H., Ulrich-Merzenich G., Panek D., et al. Immunoadsorption in the treatment of acquired haemophilia. Atheroscler Suppl 2009, 10:122-125.
11. Zeitler H., Ulrich-Merzenich G., Panek D., et al. The benefit of extracorporeal treatment for the acute und long-term outcome of patients with life threatening acquired haemophilia. Transfus Med 2012, [in progress].
12. Akeno N., Smith E.P., Stefan M., et al. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 2011 Apr 15, 186(8):4693-4706. [Epub 2011 Mar 14].
13. Mahendra A., Padiolleau-Lefevre S., Kaveri S.V., Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired Haemophilia A. Brit J Haematol 2011, 156:3-12.